Pivotal phase II study of resiniferatoxin for the treatment of cancer pain
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2016
At a glance
- Drugs Resiniferatoxin (Primary)
- Indications Cancer pain
- Focus Registrational; Therapeutic Use
- 08 Aug 2016 Planned initiation date changed from 1 Dec 2015 to 1 Jan 2017, as per Scintilla Pharmaceuticals media release.
- 08 Aug 2016 According to a Scintilla Pharmaceuticals media release, this study is expected to initiate in early 2017.
- 20 May 2014 New trial record